Medically reviewed by Douglas A. Nelson, MD The treatment for leukemia depends on many factors, including the type, subtype, and stage of the disease, and a person’s age and general health. Treatment ...

It is important to distinguish de novo CML-BP from Ph-positive ALL before allogeneic hematopoietic cell transplantation. The effect of BCR::ABL1 mutation status on outcomes of hematopoietic cell ...

Researchers sought to determine whether asciminib would have long-term benefit in patients with newly-diagnosed Philadelphia chromosome-positive chronic phase CML.

Scemblix outperformed standard TKIs in 96-week MMR rates, showing significant efficacy in CML treatment. FDA accelerated approval was based on 48-week data, highlighting Scemblix's early promise.

Researchers recently calculated the estimated savings over a 30-year period with regard to CML patients who attempt to get off their TKI therapy. In what they referred to as a 'conservative' estimate, ...

Clinical-stage precision oncology company Enliven Therapeutics Inc. (Nasdaq: ELVN) was bullish in its recent earnings report ...

When the Food and Drug Administration approved Gleevec to treat a form of leukemia in 2001, it ushered in a new era in cancer ...

Terns Pharmaceuticals Inc. (NASDAQ:TERN) stock is trading higher on Monday, with a session volume of 24.36 million, compared to its average volume of 1.31 million, according to Benzinga Pro. The ...